PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New therapy to overcome treatment-resistant skin cancers

2025-06-02
(Press-News.org) A study has revealed why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumours and identifies a new combination treatment.

Publishing in Nature Immunology, the international group of experts led by scientists at Newcastle University, UK has identified the biological mechanisms leading to a revolution in our understanding of ICB resistance.

They identify a new combination strategy for treating ICB resistant metastatic skin cancers and suggest  that this can also be of benefit in the immunotherapy treatment of other solid cancers.

Dr Shoba Amarnath, Reader in Immune Regulation at Newcastle University led the research. She says: “Identifying this mechanism is important as it identifies patients who will not respond to single agent ICB treatment such as anti-PD1 antibody therapy, but are most likely to benefit from the new combination therapy that we have identified, anti-CD30.

“By simply adding anti-CD30 for these patients, we can improve their response to cancer and avoid costly delays.

“Although our work was limited to skin cancer, we believe this new combination treatment will also benefit patients with lung, bowel, pancreatic and other solid cancers who are currently not responding to treatment with ICB monotherapy.”

ICB

The use of immune checkpoint blockade (ICB) therapy in solid cancers has shown unexpected success in a significant minority of patients. However, resistance to ICB therapy affects more than 60% of cancer patients who are prescribed this medicine. These medicines are expensive and cause significant toxicity in non-responders.

ICB therapy, or immune checkpoint blockade, is a type of immunotherapy that aims to unlock the body's natural immune system to attack cancer cells. It works by targeting and blocking specific "checkpoints" in the immune system that normally help to keep it in check, allowing T cells to recognise and destroy cancer cells more effectively. 

ICB resistance understood

The scientists demonstrate that ICB resistance occurs due to their effect on a type of immune cell called T regulatory cells (Tregs). Selective blocking of the ICB protein PD-1 on Tregs alone paradoxically enhances cancer growth in these patients. They studied this using a new mouse model where PD1 deficiency was limited to Treg cells together with samples from human skin cancer patients to study ICB resistance. This new mouse was engineered by scientists at Newcastle University to specifically allow understanding of ICB resistance.

They found ICB therapy enhances the expression of several alternate checkpoint proteins in Tregs that drives enhanced cancer growth. In the paper they describe how targeting one of these immune suppressive proteins called CD30, can rescue, or overcome, checkpoint therapy resistance in skin cancer. As an opportunity for future study, an immunotoxin (an anti-CD30 immunotoxin, Brentoximab Vidotin; BV) targeting this protein is already available for treatment of blood cancers and the team believe this has potential as a combination therapy for other solid cancers.

There is also a significant development from a Phase II trial in the USA in patients who do not respond to ICB monotherapy. In the trial, combining anti-PD1 ICB and BV shows 24% median survival for refractory metastatic cutaneous melanoma, a  melanoma that has spread to other parts of the body and is not responding to standard treatments. This provides a significant lifesaving alternative for late stage skin cancer patients who do not respond to standard ICB regiments.

Dr. Amarnath added:  “Further progress in the laboratory has discovered new immune specific proteins and tumour growth proteins that have elevated expression in Tregs during ICB therapy. We also found that these Tregs show stem-cell like properties.

Ongoing work in the laboratory includes understanding the function and potential therapeutic value of targeting these new proteins in Tregs in skin and other solid cancers.

“We are very excited to find all these new aspects in ICB resistance biology which will not be possible without this new murine model. We believe targeting immune molecules and tumor growth proteins, will significantly enhance the efficacy of ICB in solid cancers”.

Funding for the study came from RCUK,   Medical Research Council (MRC), LEO Foundation, Academy of Medical Sciences, the National Centre for the Replacement Refinement and Reduction of Animals in Research (NC3Rs) and the National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC).

Reference: PD-1 receptor deficiency enhances CD30+ Treg cell function in melanoma. Nature Immunology. Shoba Amarnath: Newcastle University. DOI: 10.1038/s41590-025-02172-0 (note: link live after embargo lifts)

Picture caption: PD-1 deficiency enhances Treg cell pro-tumor function : Lim et al. demonstrate that Treg cells deficient in PD-1 occupy key spatial niches within the TME, with regulatory subsets organized near tumor cells dampening anti-tumor immunity (red and dark blue indicating a tumor protected by Treg cells), while cytotoxic (medium blue; red diffuse glow) and type 1 Treg cells (light blue; red diffuse glow ) are organized around immune cells driving active immune hubs.  

END


ELSE PRESS RELEASES FROM THIS DATE:

Research alert: Molecular stress in old neurons increases susceptibility to neurodegenerative diseases, study finds

2025-06-02
As the global population ages, the risk of developing neurodegenerative diseases such as dementia, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) continues to rise. But the molecular mechanisms behind the deterioration of brain cells have remained elusive. Now, a new study by University of California San Diego School of Medicine researchers has found that old neurons have unique defects resulting from molecular stress that make them especially vulnerable to neurodegeneration. “Aging ...

Study provides new insights into the genetic complexity of cancer metastasis

2025-06-02
When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic complexity. A new study from researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) provides fresh insights about how cancers evolve when they metastasize — insights that could aid in developing strategies to improve the effectiveness of treatment. The team — led by collaborators Dr. Luc Morris, a surgeon and cancer genetics research lab director at MSK, Dr. Xi Kathy Zhou, a professor of research in population health sciences at Weill Cornell Medicine, and Dr. Chaitanya Bandlamudi, a cancer genomics researcher at MSK — ...

The heart of female elite athletes adapts differently than those of male elite athletes

2025-06-02
Intensive exercise- and sport changes the heart of an athlete. Research led by Amsterdam UMC shows that the hearts of female athletes have different characteristics than those of male athletes. Whereas a thickening in combination with a dilation of the heart muscle is characteristic in male top athletes, dilation of the heart chambers is mainly seen in female elite athletes. An important observation that can help doctors to better distinguish between normal sports-related changes and possible heart disease ...

The ”immune system” of a safe and equal Europe is in danger, according to researchers

2025-06-02
The Association of ERC Grantees (AERG) expresses grave concern over the future of fundamental research in Europe. It released a statement in which it urges European leaders to protect fundamental science by increasing the autonomy of the European Research Council (ERC). Current discussions of the successor framework programme to Horizon Europe suggest it will be “tightly connected” to a European Competitiveness Fund. This greatly endangers the ERC’s autonomy and thus its mission. As behavioural scientist  Karin Roelofs, professor of ...

Does a culturally tailored quality of life intervention benefit Latina breast cancer survivors and caregivers?

2025-06-02
A recent randomized controlled trial assessed the benefits of a group-based intervention that fosters communication and coping skills in a culturally tailored way for Latina breast cancer survivors and their caregivers. The results are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. For the trial, investigators randomized 136 Latina breast cancer survivors and 136 caregivers from Washington, D.C., New York, NY, and San Jose, CA, to participate in an 8-session coping and ...

‘A love affair with the sea’: Meet a scientist who overcame hurdles to dedicate her life to studying the ocean

2025-06-02
by Dr Mary Elizabeth Livingston In my recently published paper ‘My love affair with the sea’ I describe how from a very early age I fell in love with the sea and pursued that love throughout my younger years and at university, ending up with a 40-year career as a fisheries scientist. Political changes on how women were perceived in the workplace benefitted me and I feel incredibly lucky to have had the opportunity to work in a job that has taken me to many parts of the globe and given me such a purposeful way of contributing to human and ecological wellbeing. I am originally from the UK but moved to New Zealand as a post-graduate ...

Sea change in cancer care requires urgent action to strengthen oncology workforce, care delivery

2025-06-02
Rapid advances in cancer treatment have benefitted many people, but urgent change is needed in Canada’s cancer care workforce to ensure patient care, according to an analysis published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241425. “A sea change has occurred in cancer care,” writes Dr. John Walker, an oncologist at the University of Alberta and Cross Cancer Institute, Edmonton, Alberta, with coauthors. “Although improved understanding of the genetic and molecular basis of disease has resulted ...

Board game enables autistic people to create stories about their condition

2025-06-02
A board game through which players use images on cards to develop and tell their own stories could be particularly appreciated among people with autism as it offers a means to explain their thoughts and feelings, a new study has shown. Dixit, an award-winning game published by the French company Libellud, invites participants to select one of 84 illustrated cards which they feel matches a title suggested by the designated storyteller. For this study, researchers asked 35 autistic participants – split into groups of between five and eight – to place a card that they felt best described autism, and then being asked to explain the reasoning ...

Information entropy untangles vortices and flows in turbulent plasmas

2025-06-02
Research Background: Turbulence in nature refers to the complex, time-dependent, and spatially varying fluctuations that develop in fluids such as water, air, and plasma. It is a universal phenomenon that appears across a vast range of scales and systems—from atmospheric and oceanic currents on Earth, to interstellar gas in stars and galaxies, and even within jet engines and blood flow in human arteries. Turbulence is not merely chaotic; rather, it consists of an evolving hierarchy of interacting vortices, which may organize into ...

Overall survival and quality-of-life superiority in modern phase 3 oncology trials

2025-06-01
About The Study: Although phase 3 trials are often interpreted as demonstrating superiority, overall survival and quality of life (QOL), which may be the most relevant end points to patients, are uncommonly improved. To increase the meaningfulness of late-phase research, future trial designs and regulatory processes should be refocused toward overall survival and QOL improvements. Corresponding Author: To contact the corresponding author, Alexander D. Sherry, MD, email alexanderdsherry@gmail.com. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamaoncol.2025.1002) Editor’s ...

LAST 30 PRESS RELEASES:

New insights into seasonal shifts in sleep

Estimating microbial biomass from air-dried soils: A safer, scalable approach

AI in healthcare needs patient-centred regulation to avoid discrimination – new commentary

A good soak in a hot tub might beat a sauna for health benefits

Surgery plus speech therapy linked to improved language after stroke

GP performance pay fails to drive lasting changes in quality of care

Focusing on weight loss alone for obesity may do more harm than good

In sub-Saharan Africa, 1 in 6 cancer medications found to be defective

Newborns require better care to improve survival and long-term health

EMBARGOED: New study shows almost half of hospital patients in Malawi and Tanzania have multiple health conditions

People with symptoms of chronic lung disease in Kenya face ‘catastrophic’ health costs

Sylvester Cancer Tip Sheet - June 2025

UC Davis and Proteus Space to launch first-ever dynamic digital twin into space

Olympians' hearts in focus: groundbreaking study reveals elite rowers' surprising AFib risk

Common medicine for autoimmune diseases works on giant cell arteritis

Your neighborhood may be tied to risk of inflammation, dementia biomarkers

AAN issues position statement on possible therapies for neurological conditions

Liver organoid breakthrough: Generating organ-specific blood vessels

LRA awards 2025 Lupus Insight Prize to Dr. Deepak Rao for uncovering key drivers of immune imbalance in lupus

Terasaki Institute’s Dr. Yangzhi Zhu recognized as 2024 Biosensors Young Investigator Award Recipient

NAU researchers launch open-source robotic exoskeleton to help people walk

Early farmers in the Andes were doing just fine, challenging popular theory

Seeing men as the “default” may be tied to attitudes to politicians, Black people

Risk of crime rises when darkness falls

Data from Poland, Indonesia and Nepal indicate that affectionate behavior is associated with higher relationship satisfaction - though cultural differences impact how affection is displayed and percei

"Boomerang" made from mammoth tusk is likely one of the oldest known in Europe at around 40,000 years old, per analysis of this artifact from a Polish Upper Paleolithic cave

"Shrinking" cod: how humans have altered the genetic make-up of fish

Nitrate in drinking water linked to preterm birth rates

Ancient canoe replica tests Paleolithic migration theory

Eight-month-old babies can adapt their learning style to change

[Press-News.org] New therapy to overcome treatment-resistant skin cancers